These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21956430)

  • 41. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
    Agarwal A; Chang GJ; Hu CY; Taggart M; Rashid A; Park IJ; You YN; Das P; Krishnan S; Crane CH; Rodriguez-Bigas M; Skibber J; Ellis L; Eng C; Kopetz S; Maru DM
    Cancer; 2013 Dec; 119(24):4231-41. PubMed ID: 24089344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?
    Jung KU; Kim HC; Park JO; Park YS; Park HC; Choi DH; Cho YB; Yun SH; Lee WY; Chun HK
    J Surg Oncol; 2015 Mar; 111(4):439-44. PubMed ID: 25488390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
    Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
    Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy.
    Runau F; Collins A; Fenech GA; Ford E; Dimitriou N; Chaudhri S; Yeung JM
    Int J Colorectal Dis; 2017 Mar; 32(3):341-348. PubMed ID: 27885480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer.
    Venigalla S; Chowdhry AK; Wojcieszynski AP; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E; Mahmoud NN; Reiss KA; Shabason JE
    Clin Colorectal Cancer; 2018 Sep; 17(3):e557-e568. PubMed ID: 29910004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic therapy for duodenal adenocarcinoma: An analysis of the National Cancer Database (NCDB).
    Kaslow SR; Prendergast K; Vitiello GA; Hani L; Berman RS; Lee AY; Correa-Gallego C
    Surgery; 2022 Jul; 172(1):358-364. PubMed ID: 35437164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.
    Yeung RS; Weese JL; Hoffman JP; Solin LJ; Paul AR; Engstrom PF; Litwin S; Kowalyshyn MJ; Eisenberg BL
    Cancer; 1993 Oct; 72(7):2124-33. PubMed ID: 8374871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
    De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
    Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
    Wolthuis AM; Penninckx F; Haustermans K; De Hertogh G; Fieuws S; Van Cutsem E; D'Hoore A
    Ann Surg Oncol; 2012 Sep; 19(9):2833-41. PubMed ID: 22451236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.